Suppression of FTO expression genetically or pharmacologically inhibits cell proliferation, promotes cell differentiation and resensitizes resistant t(8;21) AML cells to Cytosine arabinoside (Ara-C), via downregulating its functional downstream target IGFBP2. This evidence concerns the gene FTO and acute myeloid leukemia.